Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Avidity Biosciences Stock Blasted 42% Higher Today


A richly priced buyout seriously boosted the share price of biotech Avidity Biosciences (NASDAQ: RNA) as the stock trading week began. The company's equity rose by 42%, closing to land just below the buyout price. This leap looked quite impressive next to the S 500 (SNPINDEX: ^GSPC), as the bellwether stock indicator only increased by 1.2% on the day.

The purchasing party is global pharmaceutical company , which on Sunday divulged that it and Avidity had agreed to the acquisition. Under its terms, Switzerland-based Novartis will pay $72 per share for Avidity in an all-cash transaction. That's 46% higher than Avidity's closing share price last Friday.

Image source: Getty Images.

Continue reading


Source Fool.com

Novartis AG ADR Stock

€109.50
-0.450%
Novartis AG ADR shows a slight decrease today, losing -€0.500 (-0.450%) compared to yesterday.
Based on 5 Buy predictions and 4 Sell predictions the sentiment towards Novartis AG ADR is rather balanced.
However, we have a potential of -8.68% for Novartis AG ADR as the target price of 100 € is below the current price of 109.5 €.
Like: 0
RNA
Share

Comments